Business Context and Reporting Period
PharmaCyte Biotech, Inc. filed this Form 8-K on July 9, 2021, reporting a corporate action approved by its Board of Directors. The company is incorporated in Nevada and maintains its principal executive offices in Laguna Hills, California.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
The primary material change reported is a 1-for-1,500 reverse stock split of the Company's common stock, effective as of 12:01 A.M. Eastern Time on July 12, 2021. Key details include:
- Authorized Common Shares: Reduced from 50,000,000,000 to 33,333,334 shares.
- Par Value: Remained unchanged at $0.0001 per share.
- Preferred Stock: The number of authorized preferred shares remained at 10,000,000 and was not affected by the split.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard legal disclosures associated with the reverse stock split. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the post-split share count and trading symbol status on the relevant exchange.
- Confirm the effective date of the reverse stock split (July 12, 2021) for transaction settlement purposes.
- Review the attached Certificate of Change (Exhibit 99.1) for legal finality of the share reduction.
- Check subsequent filings for any impact on the company's compliance with listing standards.